NCT04411680 - Study of Sargramostim in Patients With COVID-19 | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

March 2, 2021

Study Completion Date

May 19, 2021

Conditions

COVID-19SARS-CoV-2

Interventions

DRUG

Sargramostim

Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF). Dosage for inhaled sargramostim: 125 mcg twice a day. Dosage for intravenous sargramostim: 125mcg/m2/day given over a 4 hour period.

DRUG

Standard of care

Standard of care for COVID-19

Trial Locations (11)

10310

Richmond University Medical Center, Staten Island

21801

TidalHealth Peninsula Regional, Inc, Salisbury

27834

Brody School of Medicine at East Carolina University, Greenville

43614

University of Toledo Medical Center, Toledo

65212

University of Missouri Health Care, Columbia

69101

Great Plains Health, North Platte

77030

Memorial Hermann Hospital Affiliated with the University of Texas Health Science Center at Houston, McGovern Medical School, Houston

84108

University of Utah Health, Salt Lake City

92835

St. Jude Medical Center, Fullerton

92868

St. Joseph Hospital of Orange, Orange

94109

California Pacific Medical Center - Van Ness Campus, San Francisco